SRP72: A Protein Involved in The Regulation of Cell Signaling and Tissue Repair

Target Name: SRP72

NCBI ID: G6731

SRP72

SRP72: A Protein Involved in The Regulation of Cell Signaling and Tissue Repair

SRP72, also known as epididymis luminal protein 103, is a protein that is expressed in the epithelial cells of the vas deferens in the male reproductive system. It is a member of the serpins (serine protease inhibitors) family and is known for its role in the regulation of cell signaling and tissue repair.

SRP72 is expressed in the epithelial cells of the vas deferens and is involved in the formation of tight junctions, which are a type of cell-cell adhesion that helps to maintain the integrity of the vas deferens. It is also involved in the regulation of the production of matrix proteins, which are important for cell signaling and tissue architecture.

In addition to its role in cell signaling and tissue repair, SRP72 is also thought to be a potential drug target. Its involvement in the regulation of cell signaling and tissue architecture makes it a potential target for small molecules that can modulate these processes. Additionally, its expression in the vas deferens suggests that it may be a useful biomarker for the diagnosis and treatment of vasal injuries, such as urinary tract infections or vasectomies.

SRP72 has been shown to play a role in the regulation of cell signaling and tissue repair in a variety of organisms, including humans. For example, studies have shown that SRP72 is involved in the regulation of cell proliferation and differentiation in the vas deferens, and that it plays a role in the formation of tight junctions.

In addition to its role in cell signaling and tissue repair, SRP72 may also be a potential drug target for the treatment of certain diseases. Its involvement in the regulation of cell signaling and tissue architecture makes it a potential target for small molecules that can modulate these processes and improve therapeutic outcomes. For example, studies have shown that SRP72 may be involved in the regulation of cancer cell growth and metastasis, and that inhibiting its activity may be a useful approach for the treatment of certain types of cancer.

Overall, SRP72 is a protein that is expressed in the epithelial cells of the vas deferens and is involved in the regulation of cell signaling and tissue repair. Its potential as a drug target and biomarker makes it an interesting target for research into the regulation of these processes and the development of new therapeutic approaches. Further studies are needed to fully understand its role in these processes and its potential as a drug target.

Protein Name: Signal Recognition Particle 72

Functions: Component of the signal recognition particle (SRP) complex, a ribonucleoprotein complex that mediates the cotranslational targeting of secretory and membrane proteins to the endoplasmic reticulum (ER) (PubMed:34020957). The SRP complex interacts with the signal sequence in nascent secretory and membrane proteins and directs them to the membrane of the ER (PubMed:34020957). The SRP complex targets the ribosome-nascent chain complex to the SRP receptor (SR), which is anchored in the ER, where SR compaction and GTPase rearrangement drive cotranslational protein translocation into the ER (PubMed:34020957). Binds the signal recognition particle RNA (7SL RNA) in presence of SRP68 (PubMed:27899666, PubMed:21073748). Can bind 7SL RNA with low affinity (PubMed:27899666, PubMed:21073748). The SRP complex possibly participates in the elongation arrest function (By similarity)

The "SRP72 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SRP72 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets